Current Cancer Drug Targets
Current Cancer Drug Targets is published by Bentham Science Publishers as a subscription journal (ISSN 1568-0096). No open-access article processing charge is listed; publishing is typically via subscription. Its OpenAlex h-index is 115. Figures on this page are sourced from OpenAlex and DOAJ and should be confirmed on the journal’s own site before submission.
Cost to publish
Subscription
No open-access fee found. Publishing is typically free to the author.
Checked · How we source APCs
Time to publication
—
Not reported to DOAJ.
h-index
115
OpenAlex citation statistic. Not a Journal Impact Factor.
2-year mean citedness
1.9
Average citations to articles from the previous two years.
What it costs to publish here
We could not find a published fee for Current Cancer Drug Targets. As a subscription or hybrid journal, publishing is normally free unless you choose the open-access option.
Peer review and licensing
| Review model | Not reported |
|---|---|
| Licence | Not reported |
| Author keeps copyright | Not reported |
| Plagiarism screening | Not reported |
| Editorial board | Not linked in DOAJ |
| Languages | Not reported |
Verification data is limited because this journal is not listed in DOAJ. Many long-established subscription journals are not in DOAJ and this does not indicate any quality concern.
Scope
The subjects Current Cancer Drug Targets publishes most, derived from the topics assigned to its indexed articles.
Publication record
| Indexed articles | 2,109 |
|---|---|
| Total citations | 66,434 |
| i10-index | 1,215 |
| Most recent indexed article | 2026 |
| All ISSNs | 1568-0096, 1873-5576 |
Counts reflect what OpenAlex has indexed and will differ from the publisher's own figures. We do not show a founding year: OpenAlex's first-publication dates are distorted by mis-dated records — it puts PLoS ONE in 1806 — and we would rather omit a number than print one we cannot stand behind.